Business Context and Reporting Period
Company: PAVmed Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2015
Business Overview: PAVmed is a medical device company in the development stage, organized to advance a pipeline of innovative products from concept to commercialization. The company employs a capital and time-efficient business model, utilizing outsourced development and contract manufacturing. As of the filing date, the company had not generated any revenue and was preparing for an initial public offering (IPO).
Key Financial Metrics
| Metric | Year Ended Dec 31, 2015 | Period Inception to Dec 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,776,600) | $(274,384) |
| Operating Expenses | $1,776,600 | $274,384 |
| - Formation & Operating Costs | $1,287,273 | $263,239 |
| - Research & Development | $489,327 | $11,145 |
| Cash Position (End of Period) | $767,268 | $839,077 |
| Net Cash Used in Operating Activities | $(1,249,605) | $(30,135) |
| Net Cash Provided by Financing Activities | $1,177,796 | $869,212 |
| Accumulated Deficit | $(2,050,984) | $(274,384) |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by approximately $1.5 million year-over-year. Formation and operating costs rose by roughly $1.0 million, driven by increased executive compensation (including non-cash contributed services), marketing services, and executive search fees. R&D costs surged by approximately $478,000 as the company expanded contract research spending across all five lead product candidates, compared to limited design costs in the prior period.
- Capital Raising: In 2015, the company raised approximately $1.25 million through the exercise of warrants. In the prior period, capital was raised primarily through the sale of common stock and warrants ($923,212).
- Stock Structure: A 2.7872582-for-1 stock split was effectuated in September 2015, resulting in 12,250,000 shares of common stock outstanding as of April 11, 2016.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows from operations, and an accumulated deficit. The company's ability to continue operations is dependent on the successful consummation of its IPO or securing additional financing.
- Outlook: Management estimates that existing cash and anticipated IPO proceeds will fund operations into early 2017. The company plans to submit 510(k) applications for two of its five lead products in 2016 and early 2017.
- Pipeline Status: The company has five lead projects (PortIO, Caldus, CarpX, NextCath, NextFlo) in various stages of development. None have received regulatory approval or generated revenue. Estimated costs to achieve initial regulatory clearance range from $1.5 million to $3.0 million per product.
- Risks: Key risks include the failure to achieve regulatory approval, inability to raise additional capital, intense competition from established medical device companies, and reliance on third-party manufacturers and distributors. The company also faces risks related to intellectual property protection and potential conflicts of interest with management's other business ventures.
Investor Verification Checklist
- IPO Status: Verify the current status of the initial public offering, as the company's liquidity and going concern status depend on its successful completion.
- Regulatory Pathways: Confirm the specific FDA regulatory pathway (510(k) vs. PMA) for each lead product, as this significantly impacts time-to-market and capital requirements.
- Related Party Transactions: Review the management services agreements with affiliates (HCP/Advisors LLC and Pavilion Holdings Group LLC) and the terms of the patent acquisition from a related party.
- Executive Compensation: Examine the contingent salary arrangements for the CEO and the vesting schedules for options granted upon IPO consummation.
- Warrant Dilution: Assess the impact of the 9.56 million outstanding warrants (exercise price $0.90) on future share count and potential dilution.